369 completed, 43 unknown, 32 terminated, 29 recruiting. 521 Phase 2, 103 Phase 1, 71 Phase 3.
Follow Vector Borne Diseases: new trials by email Literature Review of Vector Borne Diseases trials Research Report on Vector Borne Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mast Cell Treatment in Post-tick Bite Illness (PTBI) Ketotifen, fexofenadine, Cromolyn Sodium - Tick Bites, Mast Cell Activation Disorders | Phase 2 | Not yet recruiting | University of North Carolina, Chapel Hill | 50 | 2027-01-01 | 2026-11-09 |
| This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria SJ733/TQ placebo, CQ/TQ Placebo, CQ/TQ - Malaria, Malaria Vivax | Phase 2 | Not yet recruiting | R. Kiplin Guy | 104 | 2026-12-01 | 2026-10-21 |
| Transmission-Blocking Vaccine Pvs230D1-EPA/Matrix-M in Healthy Malaria-Naive Adults Using a Plasmodium Vivax Controlled Human Malaria Infection and Transmission Model Plasmodium vivax Challenge Agent Derived from PvHMB-CCE001, Pvs230D1-EPA/Matrix-M - Healthy Volunteers, Malaria | Phase 1 / Phase 2 | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 220 | 2026-11-18 | 2026-11-13 |
| Different Treatment Frequencies for Hepatic Fibrosis Due to Schistosomiasis Praziquantel 40 mg/kg per dose given once annually, Praziquantel 40 mg/kg given three times per year - Schistosomiasis, Schistosoma Mansoni | Phase 2 / Phase 3 | Not yet recruiting | Rhode Island Hospital | 600 | 2026-11-01 | 2026-08-12 |
| A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria GSK3772701 600 mg, GSK3772701 900 mg, GSK3772701 150 mg - Malaria, Falciparum | Phase 2 | Recruiting | GlaxoSmithKline | 70 | 2026-10-07 | 2026-11-10 |
| Evaluation of IXCHIQ® Vaccine Immunogenicity IXCHIQ vaccine - Healthy Adult, Healthy Adolescents | Phase 2 | Not yet recruiting | Mauro Martins Teixeira | 75 | 2026-09-24 | 2026-09-29 |
| Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative) Emetine Hydrochloride 6mg, Placebo, Emetine Hydrochloride 12mg - Dengue | Phase 2 / Phase 3 | Recruiting | Johns Hopkins University | 600 | 2026-09-01 | 2026-10-13 |
| Tafenoquine Drug Levels in Small Children Chloroquine, Tafenoquine - Plasmodium Vivax Malaria, Vivax Malaria | Phase 2 | Not yet recruiting | University of Oxford | 20 | 2026-09-01 | 2026-09-22 |
| PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in Mali PfSPZ-LARC2 Vaccine, Normal Saline - Malaria (Plasmodium Falciparum) | Phase 2 | Recruiting | Sanaria Inc. | 300 | 2026-07-20 | 2026-07-23 |
| UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF Favipiravir, Ribavin, Optimised Standard of Care - Crimean-Congo Hemorrhagic Fever | Phase 2 | Recruiting | Liverpool School of Tropical Medicine | 378 | 2026-06-04 | 2026-08-07 |
| Ceftriaxone for Post-Treatment Lyme Disease Ceftriaxone treatment, Placebo - Post-Treatment Lyme Disease Syndrome | Phase 1 / Phase 2 | Withdrawn | Hackensack Meridian Health | 2026-05-14 | 2026-05-18 | |
| Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults Genetically attenuated PfSPZ Vaccine, Normal Saline (0.9% Sodium Chloride) - Malaria (Plasmodium Falciparum) | Phase 2 | Recruiting | Sanaria Inc. | 180 | 2026-05-04 | 2026-06-01 |
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age) mRNA-1982, Placebo - Lyme Disease | Phase 2 | Active not recruiting | ModernaTX, Inc. | 366 | 2026-04-29 | 2026-08-03 |
| Adaptive Dengue Antiviral Platform Trial Molnupiravir 400 mg, VIS513 (a monoclonal antibody), Remdesivir 100mg - Dengue, Antiviral Drugs | Phase 2 | Recruiting | Oxford University Clinical Research Unit, Vietnam | 500 | 2026-04-20 | 2026-09-28 |
| A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age. BBV87 Chikungunya vaccine, Placebo - Active Immunisation for Chikungunya Virus Infection | Phase 2 / Phase 3 | Recruiting | Bharat Biotech International Limited | 1000 | 2026-04-20 | 2026-04-29 |
| A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2) CP-COV03, Placebo - Dengue | Phase 2 / Phase 3 | Recruiting | Hyundai Bioscience Co., Ltd. | 210 | 2026-04-09 | 2026-07-10 |
| Postpartum 8-aminoquinoline Breast Milk Study Daily primaquine (0.5 mg/kg per day) for 14 days given with food food and water, Daily primaquine 1 mg/kg per day for 7 days given with food and water, Single-dose tafenoquine given with food and water to prevent gastrointestinal discomfort - Drug Pharmacokinetics in Healthy Volunteers | Phase 2 / Phase 3 | Not yet recruiting | Curtin University | 60 | 2026-04-01 | 2026-03-18 |
| Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2) Resomelagon, Placebo, Standard Treatment - Dengue Fever | Phase 2 | Recruiting | Federal University of Minas Gerais | 120 | 2026-03-20 | 2026-09-15 |
| A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure TP-05 (lotilaner) Low Dose, TP-05 (lotilaner) High Dose, Placebo - Lyme Disease | Phase 2 | Active not recruiting | Tarsus Pharmaceuticals, Inc. | 722 | 2026-03-09 | 2026-07-09 |
| L9LS-R21 Interaction Single dose of 1800 mg L9LS SC (12mL), Placebo 12 mL SC, Single dose of 225 mg L9LS SC (1.5mL) - Malaria | Phase 2 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-03-01 | 2026-04-09 |
Showing 20 of 521. Sign in to see all of them.
Malaria (177) · Malaria, Falciparum (108) · Dengue (63) · Leishmaniasis, Cutaneous (40) · Malaria, Vivax (29) · Leishmaniasis (27) · Severe Dengue (21) · Chagas Disease (15) · Encephalitis, Japanese (14) · Schistosomiasis (13) · Chikungunya Fever (12) · Leishmaniasis, Mucocutaneous (12) · Lyme Disease (12) · Encephalitis, Tick-Borne (10) · Yellow Fever (10)
Infections (512) · Mosquito-Borne Diseases (368) · Parasitic Diseases (356) · Protozoan Infections (333) · RNA Virus Infections (129) · Arbovirus Infections (126) · Virus Diseases (125) · Flaviviridae Infections (100) · Flavivirus Infections (100) · Euglenozoa Infections (86) · Hemorrhagic Fevers, Viral (75) · Malaria (70) · Skin and Connective Tissue Diseases (60) · Skin Diseases, Infectious (59)
Artemether, Lumefantrine Drug Combination (23) · Primaquine (22) · Chloroquine (19) · miltefosine (19) · fanasil, pyrimethamine drug combination (16) · Artesunate (15) · Azithromycin (15) · Amodiaquine (14) · Saline Solution (14) · Sodium Chloride (13) · Ivermectin (12) · tafenoquine (12) · Meglumine Antimoniate (11) · Vaccines (11) · Rabies Vaccines (9)
U.S. Army Medical Research and Development Command (49) · University of Oxford (40) · National Institute of Allergy and Infectious Diseases (NIAID) (28) · GlaxoSmithKline (22) · London School of Hygiene and Tropical Medicine (21) · Sanofi Pasteur, a Sanofi Company (19) · Drugs for Neglected Diseases (16) · Pfizer (16) · Novartis Pharmaceuticals (15) · Medicines for Malaria Venture (13) · Sanofi (11) · Oswaldo Cruz Foundation (7) · Sanaria Inc. (7) · Heidelberg University (6) · Hospital Universitário Professor Edgard Santos (6)
United States (87) · Brazil (38) · Burkina Faso (35) · Thailand (34) · Kenya (33) · Mali (32) · Colombia (25) · Gabon (23) · Uganda (23) · United Kingdom (21) · India (18) · Vietnam (17) · Bolivia (14) · Democratic Republic of the Congo (14) · Ghana (14)
Kassoum Kayentao, MD, MPH, PhD (5) · Adrian VS Hill, D.Phil, FRCP (4) · James McCarthy, Prof (4) · Adrian V S Hill, MD (3) · Anthony Cardile, DO (3) · Brian Greenwood, FRCP, FRS (3) · Patrick E Duffy, M.D. (3)
PMID 39377226, PMID 40099800, PMID 28495354, PMID 42253092, PMID 19150418, PMID 2022660, PMID 21298114, PMID 21443960, PMID 23284726, PMID 23433102, PMID 23877689, PMID 23899517, PMID 23962071, PMID 25211344, PMID 26292027, PMID 26292257, PMID 26571311, PMID 26881924, PMID 27695088, PMID 28472957, PMID 29324864, PMID 31672143, PMID 32932330, PMID 33998661, PMID 34179977, PMID 35664997, PMID 36875126, PMID 38830375, PMID 39308445, PMID 39356094, PMID 41176969, PMID 10190913, PMID 10501745, PMID 11832638, PMID 12011004, PMID 12663340, PMID 15069048, PMID 15714427, PMID 15838784, PMID 16269927, PMID 16338450, PMID 16503464, PMID 16837678, PMID 16904798, PMID 17213921, PMID 17442466, PMID 17707447, PMID 18231580, PMID 18270560, PMID 18286187
2014 (6), 2016 (4), 2015 (3), 2018 (2), R01NS074409 (2), R01AI184979 (1), R01HD095562 (1), R01HL086488 (1), R01NS102176 (1), U01AI065683 (1), U01AI129783 (1), U01AI141981 (1), U01AI195203 (1)